Embecta Gestione
Criteri Gestione verificati 3/4
Embecta Il CEO è Dev Kurdikar, nominato in Apr2022, e ha un mandato di 4.42 anni. la retribuzione annua totale è $ 9.40M, composta da 10.4% di stipendio e 89.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.42% delle azioni della società, per un valore di $ 3.97M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.1 anni e 4.4 anni.
Informazioni chiave
Dev Kurdikar
Amministratore delegato
US$9.4m
Compenso totale
| Percentuale dello stipendio del CEO | 10.39% |
| Mandato del CEO | 4.4yrs |
| Proprietà del CEO | 1.4% |
| Durata media del management | 3.1yrs |
| Durata media del Consiglio di amministrazione | 4.4yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Seeking Alpha • Aug 25
The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products
Summary Embecta offers a compelling deep value opportunity, trading at a P/E below 3x and free cash flow yield above 50%. Despite slightly declining sales and excessive debt, EMBC's high gross margins (59.6%) and market leadership position support a bullish 12-month target of $8-10 per share. Technical momentum has turned positive, with insider buying and extended short interest setting up the potential for a sharp rebound if fundamentals stabilize. I rate EMBC a Buy under $7, with Strong Buy territory pegged below $4, citing takeover potential and defensive sector appeal amid market rotation. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 14
EMBC: Wound Care Expansion Will Support Future Upside Despite Legal And Medtech Headwinds
Analysts have cut their Embecta price targets sharply, with one key target moving from $11 to $3 as they factor in weaker medtech sentiment, concerns about utilization and inflation, and a shift in investor focus toward data centers instead of healthcare. Analyst Commentary Recent research on Embecta highlights a sharp reset in expectations as analysts reassess the stock against a tougher backdrop for medtech valuations, higher inflation, and investor interest shifting toward data centers.
Aggiornamento narrativa • Jun 29
EMBC: Medtech Repricing And Index Removals Will Pressure Future Returns
Analysts have reduced their price target for Embecta to $3 from $11, citing updated views on medtech valuations, regulatory and utilization concerns, and a reset in expectations for revenue growth, profit margins, and forward P/E multiples. Analyst Commentary Recent Street research on Embecta points to a more cautious stance, with multiple bearish analysts trimming price targets and reassessing the stock in light of sector wide pressures in medical technology and concerns around utilization and regulation.
Aggiornamento narrativa • Jun 15
EMBC: Medtech Reset And Buybacks May Support Future Rebound Potential
Embecta's analyst price targets have been sharply reset lower, with one major firm cutting its view to $3 from $11 as analysts factor in what they see as tougher medtech valuations tied to slower product cycles, healthcare utilization concerns, inflation pressures after recent conflicts, and investor preference for data center exposure over healthcare. Analyst Commentary Recent research commentary around Embecta has centered on recalibrating expectations for medtech stocks in light of slower product cycles, healthcare utilization questions, and cost pressures tied to inflation.Aggiornamento narrativa • Jun 01
EMBC: Sector Reset And Buybacks Will Shape Future Upside Potential
The Street’s view on Embecta has reset sharply, with the average analyst price target moving from about $11 to around $5 as analysts recalibrate for lower P/E assumptions and sector wide pressure on medtech valuations. This pressure is tied to slower product cycles, utilization concerns, higher inflation, and capital flowing to data centers instead of healthcare.Aggiornamento narrativa • May 16
EMBC: Reset Expectations And Capital Returns Will Shape The Bullish Case
Analysts have reset Embecta's fair value estimate from $25 to $11, reflecting lower price targets after recent cuts from firms that cited updated views on growth, profitability and risk. Analyst Commentary Recent research updates point to a more cautious stance on Embecta's valuation, with several firms lowering their price targets and, in at least one case, issuing a downgrade.Aggiornamento narrativa • Apr 30
EMBC: Wound Care Expansion Will Support Future Upside Despite Lower Price Targets
Analysts have trimmed their targets on Embecta by $2 to $3, citing updated expectations that align with an unchanged fair value estimate of $15, a steady discount rate of 12.33%, and consistent long term assumptions for revenue trends, profit margin, and a future P/E of about 7.9x. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed fair value estimate of $15 and implied P/E of about 7.9x as leaving room for the share price to close part of the gap if execution on the existing plan remains consistent.Aggiornamento narrativa • Apr 15
EMBC: Higher Discount Rate And Wound Care Expansion Will Support Future Upside
Analysts have adjusted Embecta's implied fair value price target from $16.67 to $15.00, reflecting updated views on discount rates, revenue trends, profit margins and future P/E assumptions following recent research, including price target cuts from both Mizuho and BTIG. Analyst Commentary Recent research updates point to a more cautious stance on Embecta, with the lower implied fair value aligning with trimmed price targets and more conservative assumptions around growth, profitability and P/E levels.Aggiornamento narrativa • Feb 18
EMBC: Future M&A And Margin Pressures Will Shape Balanced Outlook
Analysts have maintained Embecta's price target at $11.00, citing updated assumptions that include a slightly lower discount rate, softer revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Embecta is actively exploring mergers and acquisitions, with leadership emphasizing a focus on chronic care drug delivery where the company can use its manufacturing strengths and growing B2B channel (Key Developments).Articolo di analisi • Feb 12
Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively
The market seemed underwhelmed by the solid earnings posted by Embecta Corp. ( NASDAQ:EMBC ) recently. We have done...Articolo di analisi • Feb 09
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Investors in Embecta Corp. ( NASDAQ:EMBC ) had a good week, as its shares rose 2.4% to close at US$10.87 following the...Articolo di analisi • Feb 08
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 17th of...Aggiornamento narrativa • Feb 03
EMBC: Future M&A Plans Will Test Balance Sheet And Earnings Multiple
Analysts now hold their fair value estimate for Embecta at US$11.00. The unchanged target reflects modest tweaks to assumptions around revenue growth, profit margin and future P/E that offset the slightly higher discount rate.Aggiornamento narrativa • Jan 20
EMBC: Future M&A Ambitions Will Heighten Risk Against Weak Earnings Multiple
Analysts have kept their fair value estimate for Embecta steady at US$11.00 while slightly adjusting underlying assumptions around discount rate, revenue growth, profit margins, and forward P/E. This reflects updated views on the company’s risk profile and earnings power without a change to the headline target.Articolo di analisi • Jan 09
Market Cool On Embecta Corp.'s (NASDAQ:EMBC) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 20x, you may...Aggiornamento narrativa • Jan 05
EMBC: Medium Term Guidance Will Balance Revenue Outlook With Margin Pressures
Analysts have modestly trimmed their price target on Embecta to 11.00 dollars, reflecting slightly higher discount rate assumptions and a marginally lower anticipated future P or E multiple, partially offset by incrementally stronger expectations for revenue growth and profit margins. What's in the News Embecta issued new fiscal 2026 guidance, projecting reported revenues between 1,071 million and 1,093 million dollars, signaling confidence in its medium term growth trajectory (Key Developments).Aggiornamento narrativa • Dec 15
EMBC: Outlook Will Balance Stabilizing Revenues With Pressured Profit Margins Through 2026
Analysts have modestly raised their price target on Embecta to 11.00 dollars from 11.00 dollars. This reflects improved expectations for a return to positive revenue growth and a higher future earnings multiple, partially offset by a higher discount rate and slightly lower projected profit margins.Articolo di analisi • Nov 28
US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results
It's been a sad week for Embecta Corp. ( NASDAQ:EMBC ), who've watched their investment drop 14% to US$12.57 in the...Articolo di analisi • Nov 01
Is Now The Time To Look At Buying Embecta Corp. (NASDAQ:EMBC)?
Embecta Corp. ( NASDAQ:EMBC ), is not the largest company out there, but it saw a significant share price rise of 36...Articolo di analisi • Sep 26
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price
Key Insights The projected fair value for Embecta is US$27.21 based on 2 Stage Free Cash Flow to Equity Embecta's...Articolo di analisi • Aug 28
Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely
Despite an already strong run, Embecta Corp. ( NASDAQ:EMBC ) shares have been powering on, with a gain of 29% in the...Aggiornamento narrativa • Aug 10
GLP-1 Partnerships Will Expand Global Healthcare Reach
The consensus price target for Embecta has been cut from $18.33 to $16.00, primarily reflecting lowered revenue growth forecasts and a declining future P/E multiple. What's in the News Embecta Corp.Articolo di analisi • Jul 04
Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)
Embecta Corp.'s ( NASDAQ:EMBC ) price-to-earnings (or "P/E") ratio of 11.4x might make it look like a buy right now...Articolo di analisi • May 22
Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 13th of...Articolo di analisi • May 09
What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?
Embecta Corp. ( NASDAQ:EMBC ), is not the largest company out there, but it led the NASDAQGS gainers with a relatively...Articolo di analisi • Mar 06
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price
Key Insights Embecta's estimated fair value is US$24.29 based on 2 Stage Free Cash Flow to Equity Current share price...Seeking Alpha • Feb 28
Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour
Summary Embecta faces headwinds from new insulin delivery technologies and GLP-1 drugs, but its valuation is compelling with a ~44% free cash flow yield on guided free cashflow. EMBC's end market is expected to witness a headwind from increased use of pump patches in comparison to traditional insulin delivery routes. Moreover, increased GLP-1 use to treat diabetes would lead to further less frequent use of EMBC's product. However, the expanding diabetes care market should partially offset these headwinds, leading to flat topline growth in the coming years. Even though the company is going to post a flat topline, its valuation is such that the business is going to go bust in some time. This situation offers a good risk reward to go long on the stock. Read the full article on Seeking AlphaSeeking Alpha • Dec 04
New Initiatives Expected To Make Embecta More Profitable
Summary Embecta Corp.'s Q4 results showed significant net income and EPS growth as well as profitability plans, and drove up the share price. The company announced a restructuring plan to streamline operations, reduce costs by up to $65 million annually, and discontinue its insulin patch pump program. Embecta aims to strengthen its core business, expand its GLP-1 therapies portfolio, and reduce debt, positioning it for profitable growth in fiscal 2025. I have upgraded the rating on EMBC stock to a Buy, expecting a 12.0% share price increase over the next year, driven by restructuring and new revenue streams. Read the full article on Seeking AlphaArticolo di analisi • Nov 29
Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15
Embecta Corp. ( NASDAQ:EMBC ) will pay a dividend of $0.15 on the 18th of December. The dividend yield will be 2.9...Articolo di analisi • Nov 07
At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?
While Embecta Corp. ( NASDAQ:EMBC ) might not have the largest market cap around , it led the NASDAQGS gainers with a...Articolo di analisi • Sep 24
It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)
Embecta Corp.'s ( NASDAQ:EMBC ) price-to-earnings (or "P/E") ratio of 12.6x might make it look like a buy right now...
Nuova narrativa • Sep 16
Expanding Global Leadership In Insulin Devices Fuels Revenue Growth And Operational Efficiencies
Strengthening the base business in insulin injection devices suggests potential for stable, growing revenues as the global demographic needing these devices increases.Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$88m |
| Mar 31 2026 | n/a | n/a | US$112m |
| Dec 31 2025 | n/a | n/a | US$140m |
| Sep 30 2025 | US$9m | US$977k | US$95m |
| Jun 30 2025 | n/a | n/a | US$84m |
| Mar 31 2025 | n/a | n/a | US$53m |
| Dec 31 2024 | n/a | n/a | US$58m |
| Sep 30 2024 | US$9m | US$894k | US$78m |
| Jun 30 2024 | n/a | n/a | US$70m |
| Mar 31 2024 | n/a | n/a | US$70m |
| Dec 31 2023 | n/a | n/a | US$55m |
| Sep 30 2023 | US$7m | US$863k | US$70m |
| Jun 30 2023 | n/a | n/a | US$47m |
| Mar 31 2023 | n/a | n/a | US$94m |
| Dec 31 2022 | n/a | n/a | US$160m |
| Sep 30 2022 | US$11m | US$791k | US$224m |
| Jun 30 2022 | n/a | n/a | US$338m |
| Mar 31 2022 | n/a | n/a | US$380m |
| Dec 31 2021 | n/a | n/a | US$408m |
| Sep 30 2021 | US$3m | US$447k | US$415m |
Compensazione vs Mercato: La retribuzione totale di Dev ($USD 9.40M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.62M ).
Compensazione vs guadagni: La retribuzione di Dev è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Dev Kurdikar (57 yo)
4.4yrs
Mandato
US$9,400,088
Compensazione
Mr. Devdatt Kurdikar, also known as Dev, Ph.D. is an Independent Director at Zimmer Biomet Holdings, Inc since June 20, 2024. He serves as Chief Executive Officer and Director at Embecta Corp. since April...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 4.4yrs | US$9.40m | 1.42% $ 4.0m | |
| Senior VP & CFO | 4.4yrs | US$3.46m | 0.55% $ 1.5m | |
| Senior VP | no data | US$3.01m | 0.46% $ 1.3m | |
| Senior VP & Chief Human Resources Officer | no data | US$1.73m | 0.15% $ 424.0k | |
| Senior Vice President of Global Manufacturing & Supply Chain | no data | US$2.07m | 0.060% $ 167.8k | |
| VP, Chief Accounting Officer & Corporate Controller | 1.8yrs | Nessun dato | 0.14% $ 389.0k | |
| VP & Head of Investor Relations | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Strategy | no data | Nessun dato | Nessun dato | |
| Senior VP & President of North America | no data | Nessun dato | Nessun dato | |
| Senior VP & President of International | no data | Nessun dato | Nessun dato | |
| Senior VP & President of North America | less than a year | Nessun dato | Nessun dato |
3.1yrs
Durata media
54.5yo
Età media
Gestione esperta: Il team dirigenziale di EMBC è considerato esperto (durata media dell'incarico 3.1 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 4.4yrs | US$9.40m | 1.42% $ 4.0m | |
| Lead Independent Director | 4.4yrs | US$333.00k | 0.047% $ 132.5k | |
| Independent Director | 4.4yrs | US$331.75k | 0.059% $ 165.0k | |
| Independent Director | 4.5yrs | US$332.00k | 0.13% $ 354.6k | |
| Independent Director | 4.4yrs | US$317.00k | 0.040% $ 112.2k | |
| Independent Director | 4.4yrs | US$328.00k | 0.049% $ 137.7k | |
| Independent Director | 4.4yrs | US$317.00k | 0.047% $ 132.5k |
4.4yrs
Durata media
60yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di EMBC sono considerati esperti (durata media dell'incarico 4.4 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/12 12:55 |
| Prezzo dell'azione a fine giornata | 2026/09/11 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/09/30 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Embecta Corp. è coperta da 6 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |
| Marie Thibault | BTIG |